Harmony Biosciences Holdings, Inc. $HRMY Shares Bought by LSV Asset Management

LSV Asset Management grew its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 24.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,488,502 shares of the company’s stock after buying an additional 293,541 shares during the period. LSV Asset Management owned 2.59% of Harmony Biosciences worth $47,037,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in HRMY. Boston Partners bought a new stake in Harmony Biosciences during the 2nd quarter valued at $19,398,000. New Vernon Capital Holdings II LLC increased its holdings in shares of Harmony Biosciences by 3,219.0% during the first quarter. New Vernon Capital Holdings II LLC now owns 488,424 shares of the company’s stock valued at $16,211,000 after purchasing an additional 473,708 shares during the period. Allianz Asset Management GmbH raised its stake in shares of Harmony Biosciences by 1,709.0% during the first quarter. Allianz Asset Management GmbH now owns 220,704 shares of the company’s stock valued at $7,325,000 after purchasing an additional 208,504 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Harmony Biosciences by 16.9% during the first quarter. American Century Companies Inc. now owns 1,288,787 shares of the company’s stock valued at $42,775,000 after purchasing an additional 186,183 shares in the last quarter. Finally, Woodline Partners LP acquired a new stake in Harmony Biosciences in the first quarter worth about $6,035,000. 86.23% of the stock is owned by institutional investors.

Harmony Biosciences Price Performance

NASDAQ HRMY opened at $33.99 on Wednesday. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $40.93. The business’s fifty day moving average is $29.63 and its two-hundred day moving average is $32.93. The stock has a market capitalization of $1.96 billion, a P/E ratio of 10.69, a P/E/G ratio of 0.44 and a beta of 0.85. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.72 and a current ratio of 3.75.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.05). Harmony Biosciences had a return on equity of 24.88% and a net margin of 22.50%.The company had revenue of $239.46 million during the quarter, compared to analyst estimates of $222.68 million. On average, research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HRMY has been the topic of several research analyst reports. Needham & Company LLC lowered their target price on shares of Harmony Biosciences from $48.00 to $41.00 and set a “buy” rating on the stock in a research note on Wednesday, September 24th. Mizuho raised their price objective on shares of Harmony Biosciences from $36.00 to $39.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. HC Wainwright cut their target price on Harmony Biosciences from $70.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, September 25th. Wall Street Zen lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Harmony Biosciences in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.50.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.